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Summary 
Trypanosomiasis is a devastating neglected tropical disease      affecting           livestock and      humans. 
Humans are susceptible to      two      Trypanosoma brucei      subspecies but protected from other      
trypanosomes      by      circulating high-density lipoprotein (HDL)      complexes called trypanosome lytic 
factors (TLFs) 1 and 2.      TLFs      contain apolipoprotein L-1 contributing to lysis and haptoglobin-
related protein (HPR), which can function as a ligand for a parasite receptor     .      TLF2 also uniquely 
contains non-covalently associated IgM antibodies, the role and origin of which remain unclear. Here, we 
show that these TLF2-associated      IgMs interact with both      HPR and alternate trypanosome surface 
proteins, including variant surface glycoprotein, likely facilitating complex biogenesis and TLF uptake 
into parasites.      TLF2-IgMs are germline antibodies that, while present at basal concentrations in 
healthy individuals, are elicited by trypanosome infection in both murine models and human sleeping 
sickness patients. These data suggest that poly- and self-reactive germline antibodies such as TLF2-
associated IgMs play a role in antimicrobial immunity. 
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Introduction  
Humans, gorillas, and certain old-world monkeys are immune to infection by the fly-transmitted 
protozoan Trypanosoma brucei brucei. Immunity to T. b. brucei is due to a primate-specific innate 
defense mechanism mediated by a subset of circulating high-density lipoprotein (HDL) complexes called 
trypanosome lytic factors (TLFs) 1 and 2 (Rifkin, 1978, Hajduk et al., 1989, Raper et al., 1999). Humans 
can be infected by T. b. rhodesiense and T. b. gambiense, both of which have evolved mechanisms to 
block TLF-mediated innate immunity (Vanhamme et al., 2003, Stephens and Hajduk, 2011, Uzureau et 
al., 2013). Both TLFs contain the primate-specific ion channel-forming protein apolipoprotein L-1 
(APOL1), which lyses the parasites by forming cation-selective pH-gated channels in the parasite 
membranes after endocytosis (Thomson and Finkelstein, 2015). To form open channels, APOL1 requires 
an initial membrane insertion step dependent on acidification in the endocytic compartments, followed by 
a neutralization step that likely occurs at the plasma membrane after endocytic recycling (Thomson and 
Finkelstein, 2015). Both TLFs also contain the primate-specific hemoglobin (HB) binding protein 
haptoglobin-related protein (HPR). HPR-HB complexes are endocytosed after binding the trypanosome 
haptoglobin-hemoglobin receptor (HPHBR) (Vanhollebeke et al., 2008), though this interaction can be 
inhibited by physiological concentrations of haptoglobin (HP)-HB complexes (Raper et al., 1996). 
Receptor-mediated endocytosis of TLF1 is dependent on the HPHBR, however, TLF2 endocytosis cannot 
be inhibited by HP-HB complexes and is therefore independent of the HPHBR (Raper et al., 1996). These 
biochemical experiments have also been supported by reverse genetics, wherein knockdown of the 
HPHBR increased T. b. brucei resistance to TLF1 by 10,000-fold, while resistance to TLF2 was increased 
by only 500-1000-fold (Bullard et al., 2012). While we cannot rule out the possibility of an interaction 
between TLF2 and the HPHBR, the data suggest that TLF2 has an alternative endocytosis mechanism and 
that TLF2 is the main lytic factor in normal human serum, as TLF1 activity is inhibited by physiologic 
HP-HB concentrations.  
 TLF2 is distinguished from TLF1 by the association of IgM antibodies with the TLF2 complex 
that may play a role in TLF2 endocytosis (Raper et al., 1999). Pentameric IgM antibodies typically bind 
with relatively low affinity and high avidity to their cognate antigen. These low-affinity TLF2-associated 
IgMs (TLF2-IgMs) are polyclonal and interact with the complex non-covalently (Raper et al., 1999). The 
exact stoichiometry is unclear, however, based on the sizes of the TLF1 (~500 kDa) and TLF2  (~1400 
kDa) complexes, we hypothesize that each TLF2 is comprised of one TLF1 (~500 kDa) and one IgM (950 
kDa). All healthy humans produce IgM antibodies as the first humoral response to infection. All healthy 
humans also produce IgM antibodies that do not undergo affinity maturation called natural or germline 
antibodies (Silosi et al., 2016). Germline antibodies are often associated with the recognition of self-
antigens, such as apoptotic debris and other damage associated molecular patterns (DAMPs), and do not 
require an infectious stimulus to be produced. TLF2-IgMs are present in every human plasma sample 
screened thus far, suggesting that they are germline antibodies that could simultaneously interact with 
both the TLF complex and with ubiquitous antigens.  
 Trypanosome parasites proliferate extracellularly in the bloodstream and interstitial spaces and 
are able to evade antibody-mediated adaptive responses by antigenic variation of their surface coat 
(Mugnier et al., 2015). Trypanosomes monoallelically express only one of 2000 alleles of the dominant 
coat protein, the variant surface glycoprotein (VSG). Mueller et al. clearly demonstrated that anti-VSG 
antibody specificities preexist in humans and mice that have never been exposed to the trypanosome 
(Muller et al., 1996). These germline anti-VSG antibodies also cross-react with – and are possibly raised 
against – DAMPs (Muller et al., 1996). Given that many germline antibodies target trypanosome surface 
proteins, and many germline antibodies are polyreactive, we hypothesized that TLF2-IgMs are germline 
antibodies that can interact with multiple trypanosome antigens with weak affinity. We report here an 
investigation into the role that TLF2-IgMs play in trypanosome immunity. We find that TLF2-IgMs 
interact with the TLF protein HPR and many trypanosome proteins, thus offering a route for TLF2 uptake 
and thereby providing primates with a second mechanism of targeting APOL1 for endocytic uptake by the 
parasite – one independent of the HPHBR.  
Results  
Coexpression of human HPR and APOL1 drives TLF2 formation in AID null mice—To biochemically 
query specific TLF component interactions, we designed a modular system which allows us to purify and 
assemble various TLF components from animal serum. We had previously reconstituted TLF1 in various 
mouse strains by transiently expressing the TLF proteins HPR and APOL1 by hydrodynamic gene 
delivery (HGD) (Kovacsics and Raper, 2014). While HGD has proven a useful tool for the study of TLF1, 
TLF2 formation has never been reported in any murine models. We hypothesize that the concentration of 
IgM antibodies available for TLF2 formation is too low in routinely used murine models to produce 
detectable levels of TLF2 after HGD. Since TLF2-IgMs are present in all analyzed human plasma 
samples, we hypothesized that TLF2-IgMs are germline antibodies. We therefore used HGD to express 
HPR and APOL1 in mice that produce germline antibodies at higher concentrations than wild type mice 
due to knockout of activation-induced cytidine deaminase (AID), which mediates somatic hypermutation 
and class switch recombination (Robbiani et al., 2008). AID-/- mice can only produce immunoglobulins of 
the M class, many of which are autoreactive species. We then analyzed plasma from mice transfected by 
HGD by size exclusion chromatography to separate TLF2 (~1400 kDa) and TLF1 (~500 kDa). These 
columns are packed with a porous matrix resin that separates molecules based on differences in size, with 
the largest molecules eluting first (more information can be accessed at 
https://www.gelifesciences.com/en/us/solutions/protein-research/knowledge-center/protein-purification-
methods/size-exclusion-chromatography#size-exclusion). Size exclusion chromatography of plasma from 
mice expressing human APOL1 and HPR revealed both TLF2-like and TLF1-like HPR- and APOL1-
containing complexes (Fig. 1B), though the TLF2-like complexes had smaller hydrodynamic radii than 
human TLF2 (Raper et al., 1999). TLF2 and TLF1 can also be separated by non-denaturing 
polyacrylamide (Weckerle et al., 2016) or agarose (Fig. S1) gel electrophoresis, which we used to 
characterize murine TLF2 complexes. Both the concentrated TLF2-containing fractions (lane 1) and the 
originating unfractionated plasma (lane 3) had APOL1 in the TLF2 range (Fig. 1C) and APOL1 was 
detected in the TLF1 range only in whole murine plasma (lane 3) (Fig. 1C). The TLF2-like complexes in 
ml 67-ml 67.5 of Figure 1A were immunoprecipitated (IP) using HPR as the target antigen, which 
precipitated both APOL1 and IgM (Fig. 1D), indicating that all three components were present in the 
same complex. Therefore, using HGD delivery in AID-/- animals we assemble TLF2 in mouse plasma. 
 
TLF2-IgMs interact with HPR—As HGD-generated TLF2 contains germline IgM from mouse plasma, we 
sought to evaluate any interactions with TLF components: human HPR, human APOL1, and murine 
apolipoprotein A-I (APOA-I), the structural protein of HDLs. Germline antibodies often interact with low 
affinity to self-antigens, so we first asked whether TLF2-IgM was polyreactive and anti-self. For that we 
used purified human TLF2 (Sup Fig. 3A-C) to probe membranes in Far western blot experiments and 
observed that TLF2-IgMs interact with various components of human and trypanosome cell lysates (Fig. 
S3). To then understand how such a polyreactive component would interact with the TLF proteins, we 
used our HGD mouse model to generate components of TLF and assess their individual interactions with 
IgM. To analyze the interaction between TLF2-IgM and native HDLs, we expressed either HPR or 
APOL1 in AID-/- mice by HGD and analyzed the mouse plasma by size exclusion chromatography. 
Expression of HPR in AID-/- mice (Fig. 2A) resulted in the formation of an HPR-HDL-IgM 
immunocomplex that co-migrated with murine apolipoprotein A-I (APOA-I), the structural protein of 
HDLs, and eluted from the column prior to the bulk of the murine HDL complexes (i.e. shifted the 
migration pattern of APOA-1, Fig. 2B). The HPR-HDL-IgM complex was validated by Co-IP (Fig. 2C). 
Expression of APOL1 in AID-/- mice (Fig. 2D) did not produce a detectable immunocomplex, and all of 
the APOL1 co-migrated with the bulk of the murine HDL and did not shift the migration pattern of 
APOA-I (Fig. 2E). Transfection by HGD did not significantly alter the total protein distribution in murine 
plasma (Fig. S4), and HGD of saline alone did not shift the migration pattern of APOA-I (Fig. 2F). These 
findings were validated through Far western experiments in which we used human TLF2-IgM to probe 
APOL1 HDLs or HPR HDLs derived from transfected mice (Fig. 2G). We found that TLF2-IgMs 
interacted with a human HPR-sized protein, but not human APOL1 (Fig. 2G). Unsurprisingly, due to the 
polyclonal IgM component, TLF2-IgMs can interact with many unidentified components of human and 
murine plasma, though the strongest detectable interaction was with the 45 kDa human HPR protein (Fig. 
2H, panel d), which is associated with TLF in vivo. We conclude that an interaction between the TLF2-
IgMs and HPR-bound HDL is required for TLF2 assembly in vivo, but that TLF2-IgMs can also interact 
with many other self-antigens with low affinity.  
TLF2-IgMs purified from human plasma interact with trypanosome proteins—While both TLF1 and 
TLF2 have been identified as trypanosome lytic factors, previous work has demonstrated that TLF2 is far 
more relevant in the context of human disease (Raper et al., 1996). Given that TLF1 and 2 differ by a 
single component (IgM) and that the trypanosome surface is densely coated with VSG (a target for IgM), 
we and others (Vanhollebeke and Pays, 2010) hypothesized that human TLF2-IgMs could facilitate TLF2 
uptake by trypanosomes via low-affinity interactions with trypanosome surface antigens. To investigate 
this in vitro, we first probed total trypanosome lysates with human TLF2-IgMs under native (dot blot) and 
denaturing (SDS-PAGE) conditions and observed interactions between TLF2-IgMs and many 
trypanosome antigens (Fig. 3A and B). Since the dominant trypanosome surface antigen, representing 10-
20% of the cell’s total protein and 99% of the cell surfeome (Shimogawa et al., 2015), is the ~60 kDa 
GPI-anchored VSG, we then investigated whether TLF2-IgMs could interact directly with VSG. To do 
so, we first isolated the GPI-anchored trypanosome proteins in their soluble form from three clones, each 
expressing a different VSG, by hypotonic lysis to enrich for VSG, as described previously (Cardoso de 
Almeida and Turner, 1983) (Fig. S5). Under native conditions, TLF2-IgMs interacted most strongly with 
the VSG3 preparation, while lower-affinity interactions were observed between TLF2-IgMs and VSGs 2 
and 13 (Fig. 3C). VSGs have been classified into multiple groups based on the distribution of cysteines 
throughout the amino acid sequence (Carrington et al., 1991). Both VSG2 and 13 are class A VSGs, while 
VSG3 is a class B VSG that is highly structurally divergent (Pinger et al., 2018), suggesting that TLF2-
IgMs may have some structural specificity, though this will require further investigation. Taken together, 
these data reveal that the polyclonal IgM component of TLF2, as it is present in the plasma of uninfected 
humans, can interact with VSG and other trypanosome proteins. Various kinetic experiments 
investigating the rate at which parasites are lysed by TLFs strongly suggest that TLF2 uptake occurs more 
rapidly than fluid phase endocytosis, despite the lack of an identified receptor (Vanhollebeke et al., 2007). 
We hypothesize that TLF2-bound VSG is internalized by the molecular sail mechanism by which 
antibody-bound VSGs are rapidly endocytosed (Engstler et al., 2007).  
TLF2-IgM production increases substantially upon trypanosome infection in wildtype mice—Given that 
human TLF2-IgMs interact with trypanosome antigens, we hypothesized that trypanosome infection 
could increase the production of IgMs that could interact with TLF2 in wildtype mice. Swiss Webster and 
A/J mice were infected with T. b. brucei for 4 days prior to treatment with diminazene aceturate to cure 
the infection. We then used HGD to express the TLF genes in the mice 12 days post-infection and 
analyzed the plasma by size exclusion chromatography at 14 days post infection (two days post-HGD 
with HPR and APOL1), during the peak of the IgM response to trypanosomes (Baral et al., 2007). Sizing 
the plasma revealed that the APOL1 protein migrated exclusively with the bulk HDL and did not shift the 
migration pattern of APOA-I in uninfected mice (Fig. 4A), while a significant portion of the APOL1 
shifted to the fractions containing larger complexes in the infected and cured mice and co-migrated with 
bulk IgM (Fig. 4A). To further investigate whether the IgM elicited by trypanosome infection in mice is 
TLF2-IgM, we used plasma from another trypanosome-infected mouse to screen for potential infection-
derived murine IgM interactions with human TLF proteins. Trypanosome infection-derived IgMs 
interacted with human HPR and another unidentified murine HDL protein (Fig. 4B, panel c), while IgM 
from uninfected mice does not recognize any HDL or TLF proteins (Fig. 4B, panel b). This may indicate 
that trypanosome infection increases the circulating TLF2-IgM pool by increasing the circulating amount 
of IgMs that can interact with the TLF protein HPR. As trypanosome infection has been shown to elicit a 
strong IgM response in mice (25), it is possible that a portion of these represent a unique population of 
TLF2-IgMs capable of being recruited into TLF2 complexes.  
Trypanosome infection increases TLF2-IgM production in sleeping sickness patients—The production of 
TLF2-IgMs in mice was likely due to an increased concentration of circulating germline IgMs that can 
interact with TLF. This suggests that there is a threshold of (or binding quality of) germline IgM 
concentration that is required in order to form detectable quantities of TLF2. In humans, TLF2-IgMs are 
present regardless of infection status. We investigated whether trypanosome infection, akin to the mice, 
would also increase the concentration of circulating TLF2-IgMs in sleeping sickness patients. We found 
that trypanosome infection led to a roughly 50-fold increase in circulating total IgM concentration (Fig. 
5A). We then analyzed the ratio of TLF2-associated APOL1 to TLF1-associated APOL1 and found that 
the ratio was substantially shifted towards TLF2 in infected individuals, while uninfected African or 
American control samples contained >95% TLF1 (Fig. 5B, Fig. S6). This suggests that, while only a 
small fraction of the circulating IgMs in healthy individuals are TLF2-IgMs, trypanosome infection 
increases that fraction by increasing the abundance of polyclonal trypanosome-reactive IgMs.  
One hallmark of trypanosome infection is an increase in circulating type II interferons (Wu et al., 
2017), which we confirmed in the study of this cohort of patient samples (Fig. 5C). Type II interferon 
signaling is known to upregulate APOL1 mRNA expression in cell culture (Zhaorigetu et al., 2008), and 
human T. b. gambiense infection stimulates APOL1 RNA upregulation (Ilboudo et al., 2012), suggesting 
that total APOL1 and thus TLF levels increase during trypanosome infection. This was demonstrably not 
the case, as we instead found that trypanosome infection did not significantly change the circulating 
APOL1 concentration relative to uninfected controls (Fig. 5D). The regulation of circulating APOL1 
concentration is likely multifactorial, and therefore we investigated whether the total amount of HDL was 
affected by trypanosome infection, as it is reduced during many other infections (Feingold and Grunfeld, 
2000). Indeed, the circulating HDL concentration (APOA-I protein) was reduced 5 to 6-fold in infected 
individuals relative to healthy controls (Fig 5E). These data reveal that trypanosome infection does not 
change the total amount of circulating TLF, defined by the total amount of circulating APOL1, but that it 
leads to a redistribution of the available APOL1 into TLF2 complexes by increasing the circulating levels 
of TLF2-IgMs.  
Taking all of these data together, we interpret that TLF1 and IgM exist in equilibrium with TLF2 
in vivo, and that the circulating concentration of TLF2 is entirely dependent on the amount of circulating 
TLF2-IgMs at any given time. Consistent with this hypothesis, purified human TLF2 samples 
reproducibly contain TLF1 (Fig. S1), likely due to a depletion of TLF2-IgMs from the sample during the 
stringent purification strategy. These data reveal that the interaction between germline IgMs and TLF1 is 
a low-affinity interaction that forms TLF2, and that this interaction likely plays a significant role in 
trypanosome immunity.  
Discussion 
Both TLF1 and TLF2 are trypanolytic protein complexes that harbor most of the same 
components, with the exception of the IgMs associated with TLF2 (Raper et al., 1999). Here, we have 
investigated the properties of the TLF2-IgMs and the nature of their association with TLF. We 
hypothesize that TLF1 and TLF2 are the same protein complex that is IgM-free as TLF1 and IgM-
associated as TLF2, and that TLF and IgM exist in equilibrium. The TLF-associated IgMs are likely 
germline antibodies, given that all tested humans have detectable levels of TLF2 (Fig. 5B) and AID-/- 
mice, which express high levels of germline IgM, produce TLF2-IgMs (Fig. 1 and 2). This hypothesis 
also stipulates that while the circulating concentration of TLF2-IgMs is high enough to mediate TLF2 
formation in trypanosome-naïve humans, an increase in the production of TLF2-IgMs would 
subsequently lead to an increase in the circulating levels of TLF2. We have indeed observed that 
trypanosome infected mice (Fig. 4A) and humans (Fig. 5B) produce more TLF2 than their uninfected 
counterparts. In the context of a trypanosome infection, it is also possible that some of the antigen adapted 
IgMs produced by somatically hypermutated B cells could associate with TLF to form TLF2. However, 
we hypothesize that a significant portion of the TLF-IgM pool is of germline origin. 
The data presented here indicate that TLF2-IgMs interact with the HPR component of TLF1 in 
order to form TLF2 (Fig. 2). HPR is a glycoprotein bound to HDL complexes via a retained signal 
peptide. This directed association ensures that the receptor binding face of HPR is consistently exposed to 
the external environment, thereby increasing the probability of binding the trypanosome HPHB receptor 
resulting in receptor-mediated uptake. TLF2 is taken up by trypanosomes independently of the HPHBR. 
We propose that the source of TLF2’s HPHBR independence is due to the 950 kDa IgM antibody 
interacting with HPR and therefore blocking the interaction with the receptor. This HPR-IgM interaction 
is non-covalent and of low affinity, such that the IgM may dissociate at any time and reveal the receptor-
binding domain, permitting HPHBR-mediated uptake. Bullard et al. found that ten thousand-fold more 
TLF1 was required to lyse parasites with decreased HPHBR expression as compared to wild type T. b. 
brucei, while only 100 fold more TLF2 was required (Bullard et al., 2012), suggesting that TLF2 uptake 
is partially dependent on the HPHBR. However, this model of TLF-IgM equilibrium may suggest that a 
fraction of the TLF in those purified TLF2 samples had disassociated from IgM, thereby forming TLF1, 
leading to HPHBR-mediated uptake. This is supported by our observation that purified TLF2 samples 
invariably contain free “dissociated” TLF1 (Fig. S1).  
TLF2-IgMs are particularly promiscuous antibodies that interact with many self (Fig. S3 and Fig. 
2) and non-self antigens (Fig. 3B and C). This remarkable polyreactivity is a classic characteristic of 
germline IgM antibodies. We hypothesize that the TLF2-specific trypanosome uptake pathway may 
involve this polyreactive property of TLF2-IgMs, whereby the decavalent IgMs could interact with both 
the TLF and the surface of the parasite simultaneously. Trypanosomes endocytose antibody-bound VSGs 
within 2 minutes of antibody binding in order to evade antibody-mediated immunity (Engstler et al., 
2007). We therefore hypothesize that TLF2-bound VSG would lead to TLF-associated APOL1 uptake by 
this same mechanism. A TLF2 uptake mechanism that depends on anti-VSG germline antibodies is 
consistent with work from Mueller et al., who revealed that auto-reactive IgMs in humans and other 
mammals recognize VSG proteins from various trypanosome isolates (Muller et al., 1996). In fact, some 
of the murine antibodies analyzed by Mueller et al. were derived from germ-free mice, thereby formally 
revealing that foreign antigen stimulus-independent systems produce anti-VSG IgMs. VSG is not the sole 
potential TLF2-IgM target epitope, as TLF2-IgMs can interact with a wide range of trypanosome antigens 
(Fig. 3B). However, the fact that VSG exists in a roughly 10,000-fold molar excess relative to all other 
trypanosome surface proteins leads us to hypothesize that it is the most relevant surface protein with 
regard to TLF2 uptake. Under this assumption, it is possible that trypanosome infection-elicited TLF2-
IgMs may afford TLFs with adaptive-like targeting potential by preferentially recognizing particular 
infection-specific VSG classes or variants. 
Having two non-redundant mechanisms of APOL1 delivery to invading trypanosomes provides 
an immunological advantage. In normal human serum, while TLF2 uptake is unabated, TLF1-mediated 
APOL1 uptake is effectively inhibited by the physiological levels of circulating HP (Raper et al., 1996). 
HP is an acute phase response protein that prevents HB-induced toxicity and is induced by inflammatory 
cytokines (Levy et al., 2010). Therefore, in both the acute phase and healthy states, TLF2-mediated 
trypanosome immunity likely predominates. However, TLF1-mediated trypanosome immunity may play 
a more prominent role when HP levels are low, such as in the case of chronic malaria infection. Malaria 
infection is associated with sharply decreased plasma HP levels as a result of cyclical hemolysis and 
subsequent HBHP complex clearance by macrophages, reviewed here (Rogerson, 2006). Human co-
infection with malaria in the context of trypanosome infection is common, as trypanosome endemic 
regions typically overlap with the distribution of malaria in Sub-Saharan Africa (Onkoba et al., 2015). 
The estimated 200 million annual cases of malaria could select for an HPHBR-mediated trypanocidal 
effect in co-infected individuals. To clarify this explicitly, we hypothesize that TLF2 is the main lytic 
component of normal human serum and that the entry of TLF2 into the parasite is dependent on low-
affinity interactions between the TLF2-IgMs and VSG, but that under conditions when circulating HP 
levels are low, TLF1 uptake will predominate.  
Human-infective trypanosomes are resistant to TLF-mediated lysis. T. b. rhodesiense parasites 
express serum resistance associated protein (SRA) that binds to and inhibits the activity of human APOL1 
(Vanhamme et al., 2003), while T. b. gambiense uses a combinatorial APOL1 resistance mechanism that 
is dependent on reduced APOL1 uptake via a mutated HPHBR and the Trypanosoma gambiense-specific 
glycoprotein (TgsGP), which is associated with the inhibition of APOL1 activity (Uzureau et al., 2013). 
However, human population studies (Cooper et al., 2017) and in vivo experiments using transgenic mice 
(Thomson et al., 2014) have revealed that the relationship between trypanosomes and human APOL1 is 
complicated. Human variants of APOL1 called G1 and G2 provide increased resistance to human-
infective trypanosomes. The G2 variant of APOL1 has a decreased affinity for the SRA protein from T. b. 
rhodesiense (Thomson et al., 2014), and humans harboring the G2 allele are 5-fold less likely to be 
infected with T. b. rhodesiense parasites (Cooper et al., 2017). The G1 variant is associated with a 3-fold 
decreased probability of developing clinical symptoms during T. b. gambiense infection (Cooper et al., 
2017), though the mechanism has not been characterized. Importantly, studies have revealed that human 
TLF can lyse T. b. gambiense parasites when TLF1-associated APOL1 uptake is increased by expressing 
the T. b. brucei HPHBR in the absence of HP (Uzureau et al., 2013). However, HP levels are elevated 
during trypanosome infections (Ngure et al., 1997), which prevents TLF1-mediated lytic activity (Raper 
et al., 1996). Thus, in individuals infected with African trypanosomes, we hypothesize that TLF2 would 
be the predominant lytic factor that prevents or controls the infection, and indeed we have observed that 
T. b. rhodesiense infected humans have markedly increased levels of circulating TLF2 relative to TLF1 
(Fig. 5B). We interpret these data as a shift in the TLF1/TLF2 equilibrium towards TLF2 due to an 
increase in the production of IgM antibodies in response to the trypanosome infection. Taken together, 
these data suggest that the balance between trypanosome immunity, control, and active infection is 
determined by the host’s APOL1 genotype and both the rate and ultimately the functional amount of 
APOL1 taken up by the parasites. We maintain that the field to this day does not have a full 
understanding of the structure and function of TLFs. Continued investigation of how these HDL 
complexes and their associated antibodies impact trypanosome immunity is crucial to understanding the 
relationship between trypanosomes and their primate hosts.  
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Figures legends 
Figure 1. Co-Expression of Human APOL1 and HPR Results in TLF2 Formation in AID-/- Mice. A. 
Schematic representation of the vector used to transiently induce TLF gene expression in AID-/- mice. The 
ubiquitin promoter (pink arrow) drives expression of both mammalian transgenes (HuAPOL1: green, 
HuHPR: orange) in order to induce gene expression in any cell type. A beta-globin intron (purple) and an 
SV40 polyadenylation signal (teal) flank all transgenes to increase mRNA stability. Beta-lactamase 
(yellow) is used for antibiotic selection during bacterial propagation in E. coli via an origin of replication 
(peach circle). B. Pooled plasma was obtained from two mice that were transiently expressing APOL1 and 
HPR. The plasma (0.75 ml) was then separated by size on a Superose 6 size 
exclusion column (1.5 by 60 cm), and the fractions were analyzed by western 
blot. The earliest eluting TLF-containing fractions (≥1000 kDa) that 
coeluted with IgM were designated TLF2, while the TLF-containing fractions 
eluting after mL 69 were designated TLF1 (≤500 kDa). C. Anti-APOL1 western 
blot of pooled ml 67 and 67.5 (TLF2) from A, transfected murine plasma (TLF1 
and TLF2), and normal human plasma (TLF1 and TLF2) after separation by 
native agarose gel electrophoresis. Lane 2 contains Ferritin and apoferrtin 
(Pharmacia) that migrates the same distance as human bulk HDL (denoted by 
**) that was used as a reference to compare relative migration distances 
across gels. A component of the marker interacts non-specifically with the 
secondary antibody at (*). D. Western blot analysis (IgM and APOL1) of a co-
immunoprecipitation using an antibody recognizing human HPR (Sigma 
H6395) of pooled ml 67 and 67.5 from A.  
 
Figure 2. TLF2-IgMs Interact with HPR. A. Schematic representation of the vector used to transiently 
induce HPR expression in AID-/- mice. The labeling is analogous to the labeling in Fig 1A. B. Western 
blots of size fractionated human HPR expressing AID-/- murine plasma (Superose 6). Milliliters 
containing IgM-HPR-HDL complexes are marked by ‘immunocomplex’ and milliliters containing HPR-
HDL that does not co-migrate with IgM are marked by ‘HPR-HDL.’ The HPR western blot was 
transferred from a non-reduced PAG which efficiently separates HPR (45 kDa) from HP (90 kDa). The 
IgM and APOA-I were transferred from a reduced PAG to follow the IgM heavy chain (63 kDa) and 
APOA-I (28 kDa) (HP and HPR beta chains co-migrate on reducing gels). C. Western blot analysis (IgM) 
of a co-immunoprecipitation of pooled milliliters 66 and 66.5 from A using an antibody recognizing 
human HPR (Sigma H6395). D. Schematic representation of the vector used to transiently induce APOL1 
expression in AID-/- mice. The labeling is analogous to the labeling in Fig 1A. E. Western blots of size 
fractionated human APOL1 expressing AID-/- murine plasma (Superose 6). F. Western blot of size 
fractionated untransfected AID-/- murine plasma (Superose 6). G. Far western blot using TLF2 as the bait 
protein to detect prey proteins in murine plasma, murine HDL, murine HDL after transfection with human 
HPR, and murine HDL after transfection with human APOL1. The band in lane 3 at ~45 kDa likely 
corresponds to human HPR as denoted by the ‘huHPR’ caption between the 35 and 55 kDa MW markers. 
H. Far western blot showing the interactions between TLF2-IgMs (bait) and prey proteins in human 
plasma, bovine plasma, murine plasma, murine HDL after mock transfection with saline, murine HDL 
after transfection with human HPR, and purified human TLF1. Four identical membranes were prepared 
and probed as indicated. Panel ‘a’ was probed with an anti-HP antibody that recognizes both HP (high 
molecular weight bands) and HPR (~45 kDa). Panel ‘b’ was probed with a secondary antibody that 
recognizes human IgM including the IgM component of TLF2. Panel ‘c’ was probed with human IgM, 
followed by the secondary antibody that recognizes human IgM. Panel ‘d’ was probed with purified 
human TLF2, followed by the secondary antibody that recognizes human IgM. Panel ‘c’ was probed with 
pooled human IgM at a concentration equimolar to that which was used in panel ‘d’. The arrowhead 
marks the 45 kDa human HPR protein, present in lanes 1, 5, and 6 of panels ‘a’ and ‘d’.  
 
Figure 3. TLF2-IgMs Purified from Human Plasma Interact with Trypanosome Proteins. A. Native dot 
blot using TLF2-IgMs as bait and non-denatured trypanosome lysates, human IgM, or human HP as prey. 
B. Far western blot using TLF2-IgMs as bait and an SDS-PAGE denatured trypanosome lysate 
preparation as prey. C. Native dot blot using TLF2-IgMs as bait and murine HDL after mock transfection 
with saline, murine HDL after transfection with human HPR, murine HDL after transfection with human 
APOL1, VSG2, 3, and 13 preparations, or non-denatured trypanosome lysate as prey. We estimate that by 
this technique, TLF2-IgMs have an approximately 5-6-fold higher affinity for VSG3 as compared to 
VSGs 2 or 13.  
 
Figure 4. TLF2-IgM Production Increases Substantially Upon Trypanosome Infection in Wildtype Mice. 
A. Anti-APOL1 western blots of size fractionated (Superdex 200 10/300) murine plasma samples 
expressing human APOL1 and HPR. Top panel: A/J mouse infected with and cured of T. b. brucei. 
Middle panel: Swiss Webster mouse infected with and cured of T. b. brucei. Bottom panel: Uninfected 
Swiss Webster mouse. B. Western blot showing the interaction between murine IgMs and SDS PAGE 
separated proteins from human plasma, bovine plasma, murine plasma after mock transfection with 
saline, murine HDL after mock transfection with saline, and murine HDL after transfection with human 
HPR. Samples were probed with non-specific murine IgM (a), healthy murine plasma (b), and murine 
plasma from a T. b. brucei AnTat 1.1-infected Swiss-Webster mouse (c). The amount of non-specific IgM 
used in ‘a’ was at an equimolar concentration relative to panel ‘c’ as determined by ELISA. The bands 
present in lane 1 cannot be identified by this technique. The bands present in lane 3 of each blot are likely 
murine IgM. The bands marked by two arrowheads below HPR (marked by one arrowhead) in lanes 4 and 
5 could correspond to murine APOA-I based on the molecular weight of the protein, although this is 
speculation.  
 
Figure 5. Trypanosome Infection Increases TLF2-IgM Production in Sleeping Sickness Patients. A-E. 
Samples were taken from patients infected with T. b. rhodesiense before or after treatment with suramin 
or melarsoprol. A. Plasma IgM levels determined by ELISA (Invitrogen) in sleeping sickness patients 
compared to control samples from healthy donors (error bars indicate the median and IQR). B. 
Determination of the ratio of TLF2-associated APOL1 to TLF1-associated APOL1 by western blot 
following native agarose gel electrophoresis in sleeping sickness patients compared to control samples 
from healthy donors (error bars indicate the median and IQR). C. Plasma IFN-gamma levels determined 
by ELISA in sleeping sickness patients compared to control samples from healthy donors (error bars 
indicate the median and IQR). The American group did not exist at the time that this analysis was 
performed and are thus not included (see Method details). D. Plasma APOL1 levels determined by 
western blot in sleeping sickness patients compared to control samples from healthy donors (error bars 
indicate the median and IQR). E. Plasma APOA-I levels determined by western blot in sleeping sickness 
patients compared to control samples from healthy donors (error bars indicate the median and IQR). 
 
Table 1. Details of Patients and Controls. Staging criteria and treatment regimens were fully described by 
MacLean et al, 2010. By definition, early cases are in the hemolymphatic stage of infection, while late 




Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be fulfilled by 
the lead contact, Jayne Raper (raper@genectr.hunter.cuny.edu).  
Materials Availability 
 This study did not generate any unique distributable reagents. 
Data and Code Availability 
 This study did not generate any digitally accessible data or code.  
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mice—To generate TLFs in mice, we transiently expressed APOL1 and HPR by HGD. The genes 
of interest were cloned into the pRG977 (Molina-Portela et al., 2008) mammalian expression vector (Fig. 
1A, 2A, and 2D). Each gene of interest is flanked by an intron (5' with respect to the coding sequence) and 
a polyadenylation signal (3' with respect to the coding sequence) to stabilize the resulting RNA 
transcripts. The expression of each gene is driven by a mammalian ubiquitin promoter, which functions in 
any murine cell type. Each plasmid contains a beta-lactamase gene for antibiotic selection and an origin 
of replication for propagation in E. coli. Plasmids are isolated from bacteria such that all contaminating 
endotoxin is removed (Qiagen). Mice were transfected by HGD as described in (Kovacsics and Raper, 
2014). Briefly, 25 μg of plasmid DNA diluted in approximately 2 to 3 milliliters of saline is then injected 
directly into the tail vein of an adult mouse (amount of saline is 10% of the weight of the mouse in vol/g). 
The majority of gene expression in mice receiving plasmids encoding TLF genes by tail vein injection is 
observed in hepatocytes. 
To generate TLF2 in mice that had increased levels of germline IgMs, we used male and female 
AID knockout mice (8-12 weeks old). To generate TLF2 in mice that had been previously infected with 
trypanosomes, we used female A/J mice (6-12 weeks old) and outbred female Swiss Webster mice (6-12 
weeks old). Trypanosome infections were carried out by infecting on day 0 with 5000 monomorphic T. b. 
brucei Lister-427 parasites intraperitoneally followed by treatment with 200 ul of 1.25 mg/ml diminazene 
aceturate on day 4 post-infection. Mice were confirmed parasite free by blood smear on days 5, 6, and 7. 
For the generation of (anti-trypanosome IgMs) antibodies used in Far western blots, mice were infected 
with 5000 pleomorphic AnTat 1.1 parasites intraperitoneally and monitored for 12 days before plasma 
harvest. 
All animal experiments were approved by the Institutional Animal Care and Use Committee at 
Hunter College, which both have currently approved Animal Welfare Assurance Agreements with the 
National Institutes of Health Office for Protection from Research Risks. 1-4 mice were housed per cage, 
and the mice were maintained on a 12-hour light cycle.   
Cell lines—The trypanosomes used in the in vivo experiments in this study were the Lister-427 
and AnTat 1.1 strains of Trypanosoma brucei brucei. The Lister-427 line was also grown in vitro using 
HMI-9 media supplemented with 10% FBS, 10% Serum Plus, and penicillin/streptomycin at 37°C with 
5% CO2. The human cell lines used in this study were HepG2 cells (ATCC HB-8065) and NTera-2 cells 
(ATCC CRL-1973). The human cells were grown in DMEM supplemented with 10% FBS. 
Human plasma—Human African trypanosomiasis patient and control plasma samples were a 
randomly selected subset of those previously described in (Maclean et al., 2007). Subjects or their 
guardians signed consent forms after receiving standard information in their local language. Protocols 
were approved by the Grampian Research Ethics Committee (Aberdeen) and the Ministry of Health 
(Uganda). Patient demographics and details of treatment are summarised in Table 1. “Before treatment” 
samples were taken on admission prior to commencement of treatment. “After treatment” samples were 
taken as part of the diagnostic confirmation of cure 6 weeks after admission. Staging criteria and 
treatment regimens were fully described previously in (MacLean et al., 2010). 
METHOD DETAILS 
Experimental design—All experiments were performed without blinding or randomization. All 
murine-based TLF2 generation experiments were repeated at least once, with representative experiments 
shown throughout the manuscript. All Far western blots were repeated extensively with reproducible 
results. All statistical analyses are detailed in “quantification and statistical analysis.” 
TLF2 detection in AID-/- mice after HGD—Mice were exsanguinated using 200 μl of heparin 
(Abraxis) per mouse 24 hours after HGD (2 mice per transgenic group; 1 mouse with saline control) and 
the isolated plasma was pooled (800 μl per group; 400 μl for saline group) for immediate size 
fractionation on a Superose 6 column (1.5 by 60 cm) via Fast Performance Liquid Chromatography 
(FPLC) (V0: 34 ml, flow rate: 0.4 ml/min, fraction size: 500 μl). Collected fractions were diluted in SDS-
PAGE loading buffer and run on 10% tris-glycine gels. Where shown, IgM, APOA-I, and APOL1 were 
visualized on the same membrane for all groups, while HPR was visualized from a separate membrane. 
The elution volumes are used in the labeling of the blots, rather than arbitrary fraction numbers, for the 
purposes of promoting future reproducibility. Fractions containing TLF2 were concentrated to a 500 μl 
volume (Centricon – Fisher Scientific) and subjected to co-immunoprecipitation (Co-IP) (APOL1/HPR 
dual expression: fractions 67 ml and 67.5 ml, HuHPR expression: fractions 65.5 ml – 67.5 ml). Co-
immunoprecipitation was performed using magnetic protein A/G beads (Thermo-Pierce). Briefly, 
antibodies were cross-linked to beads using disuccinimidyl suberate, which were then incubated with 
protein samples for either 1 hour at room temperature or overnight at 4°C. Beads were then washed 5X 
with tris-buffered saline (TBS) (pH 6.7 in order to increase the stringency of the wash steps and prevent 
non-specific interactions between the TLFs and the beads) before being boiled in SDS-PAGE gel loading 
buffer. Antibodies used for Co-IP: Anti-Hu HP mouse monoclonal (Sigma H6396), Mouse IgG1 
(Invitrogen 02-6100. All membranes for western blots were blocked using 5% milk in TBS with 0.05% 
Tween-20.  
TLF2 detection in infected and cured mice after HGD—Swiss Webster and A/J mice were 
infected on day 0 with 5000 monomorphic T. b. brucei Lister-427 parasites I.P. followed by treatment 
with diminazene aceturate on day 4 post-infection. Mice were transiently transfected with a vector 
encoding APOL1 and HPR by HGD on day 12 post infection and were subsequently exsanguinated using 
200 μl of heparin (Abraxis) per mouse on day 14 post infection. 400 μl (to maximize APOL1 yield and 
achieve detection on western blots) of plasma was immediately loaded onto a Superdex 200 10/300 
column and fractionated via FPLC (V0: 7 ml, flow rate 1 ml/min, fraction size: 500 μl). Collected 
fractions were diluted in SDS-PAGE loading buffer and run on 10% tris-glycine gels.  
Purification of human TLF2 and murine HDL—TLF2 was purified as described previously with 
modifications (Raper et al., 1999). Peripheral venous blood from healthy donors in New York (United 
States) was obtained. Approval was obtained from the institutional review board (IRB) at New York 
University School of Medicine. Briefly, the density of the isolated plasma (100 ml, HP haplotype 1-1) 
was adjusted to 1.25 g/ml using KBr. The plasma was then ultracentrifuged at 49,000 RPM, 10°C, 16 
hours. The bottom 50% of the resulting density gradient was collected and dialyzed using three changes 
of TBS-2.5 mM EDTA at 4°C. The dialyzed product was concentrated (Centricon – Fisher Scientific) to 
roughly 40 ml and sized (5 ml per run) on a Superose 6 column (1.5 by 60 cm, V0: 34 ml, flow rate: 1.5 
ml/min, fraction size: 1.5 ml). Fractions in the TLF2 range were pooled, concentrated to 10 ml, and 
immunoaffinity purified using a mouse monoclonal antibody raised against human HP that recognizes 
human HPR (Sigma H6396). The antibody was coupled via amino groups to a HiTrap N-
hydroxysuccinimide column as per the manufacturer’s instructions (GE Healthcare Bio-Sciences). The 
pooled TLF2 was then loaded onto the column and allowed to bind for 10 minutes, followed by a wash 
with five column volumes of TBS. The bound TLF2 was then eluted with a 100 mM glycine-150 mM 
NaCl solution at pH 2.8. Eluted fractions were immediately neutralized with 1.5 M Tris-HCL (pH 8), 
pooled, and concentrated. The affinity-purified sample was reduced in SDS-PAGE loading buffer 
containing β-mercaptoethanol and run on 10% polyacrylamide gels for silver staining or transferred to 
PVDF membranes for immunoblotting. The quality of the purified TLFs is shown in supplementary 
figure 2. 
Murine HDL was prepared using a simplified protocol. One day post-plasmid HGD, mice were 
sacrificed and exsanguinated. The density of the collected plasma was adjusted to 1.25 g/ml with KBr in 
12 ml of TBS and the samples were ultracentrifuged as described above (49,000 RPM, 10°C, 16 hours). 
At this point, the top 33% of the density gradient was collected, dialyzed into TBS, and concentrated. 
There is no need to separate the HDL from other lipoproteins by density, as the concentration of 
contaminating LDL is negligible in mice and can be efficiently removed by size fractionation. 
24-hour Trypanosome in vitro lysis assay—Cultured T. b. brucei Lister-427 parasites were diluted 
to 5 x 105 ml-1 in HMI-9 medium with 10% fetal calf serum (Laboratory Disposable Products) and 10% 
Serum Plus (SAFC Biosciences) and 100 μl was added to each well of an opaque 96 well plate. Parasites 
were then diluted 1:1 with serially diluted concentrations of purified human TLF2. After 20 hours of 
incubation at 37°C, 20 μl of alamarBlue (Invitrogen) was added to each well. The assay involves the 
reduction of resazurin by metabolically active cells to the fluorescent resorufin, allowing quantitation of 
non-lysed cells at 1-4 hours post-reagent addition. Where indicated, the trypanosomes were pre-treated 
for 30 minutes with 10 mM ammonium chloride (which remained present throughout the assay), a weak 
base that inhibits APOL1-mediated lysis of trypanosomes by neutralizing the endocytic compartments of 
the organism.   
Native agarose gel electrophoresis—0.7% SeaKem agarose (Lonza) was prepared in a running 
buffer composed of 90 mM Tris and 90 mM borate at pH 8.5. A pigmented Ferritin marker (Pharmacia) 
that migrates the same distance as the bulk of human HDL was used to determine when to stop gel 
electrophoresis. Protein samples were prepared via 1:1 dilution in 15% Ficoll 400 buffered with Tris-HCl. 
A total of 10 μl of concentrated (10 fold) murine TLF2 fractions or 1.5 μl of whole human or murine 
plasma was loaded into the gels and run at a constant voltage of 100V for 2 hours. Proteins were 
transferred to PVDF membranes for western blotting via capillary transfer overnight.  
Far western blotting—Protein-protein interactions were analyzed by Far western blotting, 
reviewed here (Wu et al., 2007). SDS-PAGE gels were used to separate proteins by size, which were then 
transferred to PVDF membranes. Protein samples were reduced with 100 mM β-mercaptoethanol where 
indicated. Membranes were blocked using 5% BSA in TBS with 0.05% Tween-20. Where indicated, 
membranes were then probed using 20 μg/ml of purified human TLF2, or an equimolar amount of pooled 
human IgM (Sigma, Cat: I8260), in the presence of 5% BSA in TBS with 0.05% Tween-20 for 1 hour at 
room temperature. This was followed by three washes (ten minutes each) in TBS with 0.05% Tween-20. 
Membranes were visualized using an anti-Hu IgM polyclonal antibody conjugated to HRP, meaning that 
any detectable bands would be resolved by the secondary antibody binding to the TLF2-IgM at that 
particular site. The Far western blot protocol was performed analogously for the dot blot (blot overlay 
assay) experiments with the following exception: Proteins were not denatured in SDS loading buffer in 
order to further facilitate the maintenance of native protein structure. Protein samples (2 μl) were applied 
directly to a nitrocellulose membrane and allowed to dry for ~15 minutes prior to probing.  
Quantifications of plasma proteins in humans—To quantify IgM, plasma samples were diluted 
between 10,000 and 100,000-fold prior to being screened in a commercially purchased sandwich ELISA 
(Invitrogen, biological limit of detection: 15.6 ng/ml).  
Plasma interferon (IFN) gamma concentrations were measured using ELISA (BD OptEIA, BD 
Biosciences, Oxford, UK, biological limit of detection: 1.8 pg/ml). Note that the “before treatment” data 
are a subset of values previously published in (Maclean et al., 2007) but are included for clarity and for 
comparison with “after treatment” data. Specifically, the data is reproduced in part from Fig 2a. Lorna 
MacLean et al. Spatially and Genetically Distinct African Trypanosome Virulence Variants Defined by 
Host Interferon-γ Response. The Journal of Infectious Diseases (2007) 196 (11): 1620-1628. By 
permission of Oxford University Press on behalf of the Infectious Diseases Society of America, available 
at: https://academic.oup.com/jid/article/196/11/1620/1992925?searchresult=1.  
To quantify APOL1, 0.375 ul of each plasma sample was electrophoresed on 10% 
polyacrylamide gels alongside a serially diluted sample of purified recombinant APOL1 at a known 
concentration. The gels were blotted onto PVDF membranes for western blotting and pixel density 
quantification studies via FIJI (Schindelin et al., 2012). The levels of APOA-I were measured by the same 
method except that only 10-20 nl of each plasma sample was electrophoresed alongside a serially diluted 
sample of recombinant APOA-I (Peprotech 350-11). 
The ratio of TLF2:TLF1 was calculated by western blot and pixel density quantification via FIJI 
(Schindelin et al., 2012) after native agarose gel electrophoresis. 1.5 ul of each plasma sample was 
electrophoresed for 2 hours in 0.7% agarose and blotted onto PVDF membranes. The membranes were 
probed for the presence of APOL1 which was used to indicate how much of each TLF species was 
present in each sample. The ratio was determined by comparing the pixel density of the signal 
corresponding to TLF2-associated APOL1 to TLF1-associated APOL1.  
QUANTIFICATION AND STATISTICAL ANALYSIS 
Pixel density quantifications were carried out using FIJI (Schindelin et al., 2012). Graphical and 
statistical analyses were carried out in GraphPad Prism version 7 (GraphPad Software, La Jolla, 
California, USA). Statistical analyses were only applied to the data in figure 5. Each data set was initially 
analyzed by the Kruskal-Wallis test to determine if statistically significant differences existed. If so, we 
applied individual Mann-Whitney tests to compared differences between groups before performing 
Bonferroni corrections: ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05. 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-human APOL1 (1:10,000) ProteinTech Group Cat#16139-1-AP 
Anti-human HP/R (1:10,000) Sigma Aldrich Cat#H8636 
Anti-mouse APOA-I (1:10,000) Abcam Cat#Ab20453 
Anti-human APOA-I (1:5000) Novus Biologicals Cat#NB400-147 
Anti-mouse IgM (1:10,000) Jackson Immuno 
Research Labs 
Cat#115-036-075 
Anti-human IgM (1:5000) Jackson Immuno 
Research Labs 
Cat#09-035-129 
Anti-rabbit TrueBlot (1:10,000) Rockland Antibodies Cat#18-8813-33 
Pooled human IgM Sigma Aldrich Cat#I8260 
Pooled mouse IgM Sigma Aldrich Cat#PP50 
Biological Samples 
Ugandan human plasma See table 1 N/A 
American human plasma New York University 
Medical Center 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
Sodium pyruvate Thermo Fisher Cat#MT-25-000-CI 
Bathocuprione di-sulfonic acid Thermo Fisher Cat#AC164060010 
Penicillin/Streptomycin Thermo Fisher Cat#15140122 
L-cysteine Sigma Aldrich Cat#C7352 
Hypoxanthine Sigma Aldrich Cat#H9636 
Thymidine Sigma Aldrich Cat#T1895 
2-mercaptoethanol Invitrogen Cat#21985-023 
Fetal bovine serum Gemini Bio-Products Cat#S01520; 
Lot#A95E82G 
Serum plus Sigma Aldrich Cat#14008C 
Iscoves modified DMEM Laboratory Disposable 
Products 
Cat#10-016-CV 
DMEM Laboratory Disposable 
Products 
Cat#10-017-CM 
Diminazene aceturate Sigma Aldrich Cat#D7770 
Sterile saline Thermo Fisher Cat#NC9054335 
Experimental Models: Cell lines 
Human HepG2 cells ATCC Cat#HB-8065 
Human NTera-2 cells ATCC Cat#CRL-1973 
Trypanosoma brucei Lister-427  Gift from George 
Cross 
N/A 
Trypanosoma brucei AnTat 1.1  Gift from George 
Cross 
N/A 
Experimental Models: Organisms/Strains 
Mouse A/J Jackson Laboratories Cat#000646 
Mouse Swiss Webster Taconic Biosciences SW Murine 
Pathogen Free 
Mouse AID knockout Jackson Laboratories Cat#007770 
Recombinant DNA 
Key Resource Table
pRG977-APOL1/HPR Molina-Portela et al., 





pRG977-HPR Molina-Portela et al., 





pRG977-APOL1 Molina-Portela et al., 





Software and Algorithms 
GraphPad Prism GraphPad software https://www.graphpa
d.com/scientific-
software/prism/ 




 Patients (n=21) Controls (n=19) 
Male:Female 10:11 9:10 
Median Age (range) 25 (6-65) 35 (8-59) 
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